- Home
- ZLAB vs NEA Comparison
ZLAB vs NEA Comparison
Compare ZLAB & NEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZLAB
- NEA
- Stock Information
- Founded
- ZLAB 2013
- NEA 2002
- Country
- ZLAB China
- NEA United States
- Employees
- ZLAB N/A
- NEA N/A
- Industry
- ZLAB Biotechnology: Pharmaceutical Preparations
- NEA Finance/Investors Services
- Sector
- ZLAB Health Care
- NEA Finance
- Exchange
- ZLAB Nasdaq
- NEA Nasdaq
- Market Cap
- ZLAB 3.0B
- NEA 3.5B
- IPO Year
- ZLAB 2017
- NEA N/A
- Fundamental
- Price
- ZLAB $26.91
- NEA $11.46
- Analyst Decision
- ZLAB Strong Buy
- NEA
- Analyst Count
- ZLAB 4
- NEA 0
- Target Price
- ZLAB $52.50
- NEA N/A
- AVG Volume (30 Days)
- ZLAB 960.6K
- NEA 803.4K
- Earning Date
- ZLAB 11-12-2024
- NEA 01-01-0001
- Dividend Yield
- ZLAB N/A
- NEA 4.23%
- EPS Growth
- ZLAB N/A
- NEA N/A
- EPS
- ZLAB N/A
- NEA N/A
- Revenue
- ZLAB $355,748,000.00
- NEA N/A
- Revenue This Year
- ZLAB $48.50
- NEA N/A
- Revenue Next Year
- ZLAB $47.37
- NEA N/A
- P/E Ratio
- ZLAB N/A
- NEA N/A
- Revenue Growth
- ZLAB 35.01
- NEA N/A
- 52 Week Low
- ZLAB $13.48
- NEA $9.20
- 52 Week High
- ZLAB $36.60
- NEA $11.37
- Technical
- Relative Strength Index (RSI)
- ZLAB 45.71
- NEA 35.14
- Support Level
- ZLAB $25.85
- NEA $11.84
- Resistance Level
- ZLAB $29.87
- NEA $11.92
- Average True Range (ATR)
- ZLAB 1.05
- NEA 0.08
- MACD
- ZLAB -0.18
- NEA -0.05
- Stochastic Oscillator
- ZLAB 21.98
- NEA 6.00
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
About NEA Nuveen AMT-Free Quality Municipal Income Fund of Beneficial Interest Par Value $.01
Nuveen AMT-Free Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and the alternative minimum tax applicable to individuals, by investing in an actively managed portfolio of tax-exempt municipal securities.